NEO PE Ratio & Valuation,Is NEO Overvalued

NEO Relative Valuation

NEO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NEO is overvalued; if below, it's undervalued.

Historical Valuation

Neogenomics Inc (NEO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.96 is considered Undervalued compared with the five-year average of 0.14. The fair price of Neogenomics Inc (NEO) is between 672.25 to 707.05 according to relative valuation methord. Compared to the current price of 12.83 USD , Neogenomics Inc is Undervalued By 98.09%.

Relative Value

Fair Zone

672.25-707.05

Current Price：12.83

98.09%

Undervalued

79.57

34.76

EV/EBITDA

Neogenomics Inc. (NEO) has a current EV/EBITDA of 34.76. The 5-year average EV/EBITDA is 132.96. The thresholds are as follows: Strongly Undervalued below -2466.71, Undervalued between -2466.71 and -1166.88, Fairly Valued between 1432.79 and -1166.88, Overvalued between 1432.79 and 2732.62, and Strongly Overvalued above 2732.62. The current Forward EV/EBITDA of 34.76 falls within the Historic Trend Line -Fairly Valued range.

-22.19

EV/EBIT

Neogenomics Inc. (NEO) has a current EV/EBIT of -22.19. The 5-year average EV/EBIT is -30.79. The thresholds are as follows: Strongly Undervalued below -85.45, Undervalued between -85.45 and -58.12, Fairly Valued between -3.46 and -58.12, Overvalued between -3.46 and 23.87, and Strongly Overvalued above 23.87. The current Forward EV/EBIT of -22.19 falls within the Historic Trend Line -Fairly Valued range.

1.96

Neogenomics Inc. (NEO) has a current PS of 1.96. The 5-year average PS is 4.27. The thresholds are as follows: Strongly Undervalued below -2.35, Undervalued between -2.35 and 0.96, Fairly Valued between 7.57 and 0.96, Overvalued between 7.57 and 10.88, and Strongly Overvalued above 10.88. The current Forward PS of 1.96 falls within the Historic Trend Line -Fairly Valued range.

53.77

P/OCF

Neogenomics Inc. (NEO) has a current P/OCF of 53.77. The 5-year average P/OCF is -121.07. The thresholds are as follows: Strongly Undervalued below -571.96, Undervalued between -571.96 and -346.51, Fairly Valued between 104.37 and -346.51, Overvalued between 104.37 and 329.81, and Strongly Overvalued above 329.81. The current Forward P/OCF of 53.77 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Neogenomics Inc. (NEO) has a current P/FCF of 0.00. The 5-year average P/FCF is -57.03. The thresholds are as follows: Strongly Undervalued below -297.40, Undervalued between -297.40 and -177.21, Fairly Valued between 63.16 and -177.21, Overvalued between 63.16 and 183.34, and Strongly Overvalued above 183.34. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Neogenomics Inc (NEO) has a current Price-to-Book (P/B) ratio of 1.81. Compared to its 3-year average P/B ratio of 1.86 , the current P/B ratio is approximately -2.66% higher. Relative to its 5-year average P/B ratio of 2.57, the current P/B ratio is about -29.67% higher. Neogenomics Inc (NEO) has a Forward Free Cash Flow (FCF) yield of approximately -1.12%. Compared to its 3-year average FCF yield of -2.51%, the current FCF yield is approximately -55.38% lower. Relative to its 5-year average FCF yield of -3.41% , the current FCF yield is about -67.10% lower.

1.81

P/B

Median3y

1.86

Median5y

2.57

-1.12

FCF Yield

Median3y

-2.51

Median5y

-3.41

Competitors Valuation Multiple

The average P/S ratio for NEO's competitors is 442.16, providing a benchmark for relative valuation. Neogenomics Inc Corp (NEO) exhibits a P/S ratio of 1.96, which is -99.56% above the industry average. Given its robust revenue growth of 11.90%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NEO decreased by 11.40% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -10.55 to -14.45.

The secondary factor is the Revenue Growth, contributed 11.90%to the performance.

Overall, the performance of NEO in the past 1 year is driven by Margin Expansion. Which is more sustainable.

11.90%

167.82M → 187.80M

Revenue Growth

36.97%

-10.55 → -14.45

Margin Expansion

-60.27%

-33.23 → -13.20

P/E Change

-11.40%

14.30 → 12.67

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Neogenomics Inc (NEO) currently overvalued or undervalued?

What is Neogenomics Inc (NEO) fair value?

NEO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Neogenomics Inc (NEO) is between 672.25 to 707.05 according to relative valuation methord.

How does NEO's valuation metrics compare to the industry average?

What is the current P/B ratio for Neogenomics Inc (NEO) as of Jan 09 2026?

As of Jan 09 2026, Neogenomics Inc (NEO) has a P/B ratio of 1.81. This indicates that the market values NEO at 1.81 times its book value.

What is the current FCF Yield for Neogenomics Inc (NEO) as of Jan 09 2026?

As of Jan 09 2026, Neogenomics Inc (NEO) has a FCF Yield of -1.12%. This means that for every dollar of Neogenomics Inc’s market capitalization, the company generates -1.12 cents in free cash flow.

What is the current Forward P/E ratio for Neogenomics Inc (NEO) as of Jan 09 2026?

As of Jan 09 2026, Neogenomics Inc (NEO) has a Forward P/E ratio of 79.57. This means the market is willing to pay $79.57 for every dollar of Neogenomics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Neogenomics Inc (NEO) as of Jan 09 2026?

As of Jan 09 2026, Neogenomics Inc (NEO) has a Forward P/S ratio of 1.96. This means the market is valuing NEO at $1.96 for every dollar of expected revenue over the next 12 months.

NEO Valuation